@article{HBSN22508,
author = {Xinlei Gong and Shukui Qin},
title = {Study progression of anti-angiogenetic therapy and its combination with other agents for the treatment of advanced hepatocellular carcinoma},
journal = {Hepatobiliary Surgery and Nutrition},
volume = {7},
number = {6},
year = {2018},
keywords = {},
abstract = {Hepatocellular carcinoma (HCC) is a common malignancy worldwide and is especially prevalent in the Chinese population. Treatment of advanced HCC has posed a considerable challenge to clinicians and highly effective therapies remain elusive. Angiogenesis contributes greatly to the pathogenesis, invasion and metastasis of HCC. Therefore, anti-angiogenesis therapy could be instrumental to the treatment of HCC. In recent years, several anti-angiogenesis drugs have generated significant outcomes in a few key clinical studies, and in this light, anti-angiogenesis therapy has become a critical aspect of comprehensive treatment of HCC. In this article, to provide a reference for clinicians, we review these advances and discuss the future direction of development.},
issn = {2304-389X}, url = {https://hbsn.amegroups.org/article/view/22508}
}